After reaching an all-time high of $357 billion in 2019 (as of November 30), life sciences mergers and acquisitions (M&A) is unlikely to surpass that record combined value this year—but the number of deals is likely to bounce back from a year-over-year drop, with cell and gene therapy developers expected to carry out a growing number of those deals, EY has concluded in a report . . .
The post From JP Morgan: Cell, Gene Therapy to Drive Biopharma M&A in 2020 appeared first on GEN – Genetic Engineering and Biotechnology News.
